In one study, exogenous administration of combined GLP-1R/Y2-R agonists partially mimicked the positive effects of bariatric surgery but did not lead to the anticipated overall metabolic improvements 10 suggesting other pathways are also involved
How to interpret the labs Reduced intake can change diabetes medication needs and dehydration risk
Many patients are on a combination of an SGLT2 inhibitor with a GLP-1 receptor agonist or tirzepatide (a dual agonist) and have incredible success without adverse reactions, but we are still figuring out the patient characteristics that would put them at higher risk of poor outcomes. Eli J
of water before eating, drinking, or taking any other medications, explains Scott Kipnis, M.D., medical director of bariatric and robotic surgery at Hackensack Meridian Jersey Shore University Medical Center
However, this approach has also impacted Type 2 diabetes patients access to GLP-1s by requiring some patients to try other diabetes treatments (e.g., blood sugar regulators such as sodium-glucose cotransporter-2 inhibitor Brenzavvy and dipeptidyl peptidase-4 inhibitor Onglyza) before GLP-1 approval
Effects of glucagon-like peptide 1 (7-36) amide and glucagon on amylin release from perfused rat pancreas
